Engagement of the T-cell receptor (TCR)-
Results and discussion
To begin to understand the functional involvement of Cbl-b in T-cell signaling, we assessed the effect of transiently overexpressed Cbl-b on transactivation of a luciferase reporter gene driven by NFAT-binding sites (NFAT-luc) . This NFAT transcriptional unit is derived from the interleukin-2 (IL-2) gene [10, 11] and has been widely used as an indicator for T-cell activation. Lysates of human leukemic Jurkat T cells expressing SV40 large T antigen (Jurkat-TAg cells) that had been transiently transfected with either empty vector or a plasmid encoding Cbl-b together with the NFAT-luc reporter plasmid were assayed for luciferase activity under different stimulation conditions. Overexpression of Cbl-b induced NFAT activation under resting conditions and this was enhanced upon stimulation with anti-CD3 antibody (Figure 1a) . A synergy between Cbl-b and a TCR-mediated signal was observed for the induction of NFAT activation when different amounts of anti-CD3 antibody were used for stimulation ( Figure 1b) . In contrast, overexpression of Cbl inhibited both basal and anti-CD3-stimulated NFAT activation under the same conditions. Normalization of the luciferase activity from the reporter in these experiments relative to the maximal luciferase activity induced by phorbol myristate acetate (PMA) and ionomycin or to a reference β-galactosidase activity showed similar results (see Supplementary material published with this paper on the internet). The level of Cbl-b-mediated activation of NFAT correlated with its protein expression level, as shown by titration of the plasmid amounts for transfection. Even low levels of Cbl-b induced activation of NFAT under basal and anti-CD3-stimulated conditions ( Figure 1c ).
Recent studies suggest that Cbl-family proteins participate in the regulation of the protein tyrosine kinases with which they associate [4] . We recently demonstrated that Cbl-b binds Syk and that a loss-of-function mutation (a glycine to glutamic acid substitution at position 298, G298E) in Cbl-b disrupts its interaction with Syk [9] . We then analyzed the effect of the G298E mutation on NFAT activation. Overexpression of the G298E Cbl-b mutant completely abolished Cbl-b-induced NFAT activation under basal and ionomycin-stimulated conditions (Figure 2a) . A large reduction in NFAT activity induced by this mutant compared with that induced by wild-type Cbl-b was observed under anti-CD3-stimulated conditions.
To further confirm that the G298E mutation in Cbl-b achieved its effect by disrupting the interaction between Cbl-b and Zap-70, we then examined the molecular basis of Cbl-b-Zap-70 binding. Coexpression of Cbl-b with Zap-70 caused basal-level tyrosine phosphorylation of Cbl-b, which was increased upon anti-CD3-stimulation ( Figure 2b ). In contrast, the G298E Cbl-b mutant was not tyrosine phosphorylated under resting conditions. Anti-CD3 stimulation induced only a low level of tyrosine phosphorylation of this mutant. Zap-70 coimmunoprecipitated with Cbl-b, and this interaction was enhanced by anti-CD3 stimulation. A markedly reduced amount of Zap-70 coimmunoprecipitated with the G298E Cbl-b mutant, however (Figure 2b ). Both Cbl and Cbl-b interact with Tyr316 of Syk [9, 12] , suggesting that these two molecules bind to the same site in Syk. As Cbl binds to the corresponding tyrosine residue of Zap-70 (Tyr292) [13] , we then examined whether Tyr292 in Zap-70 was also required for the interaction with Cbl-b. To this end, Jurkat-TAg cells were transfected with plasmids expressing wild-type Zap-70 or a Zap-70 mutant containing a tyrosine to phenylalanine substitution at position 292 (Y292F) together with a plasmid encoding Cbl-b. Consistent with the data in Figure 2b , Zap-70 was coimmunoprecipitated from cells expressing wild-type Zap-70 and Cbl-b (Figure 2c) . A markedly reduced amount of the Y292F Zap-70 mutant coimmunoprecipitated with Cbl-b under both resting and OKT3-stimulated conditions, however.
We recently showed that Syk binds to the amino-terminal phosphotyrosine-binding (PTB)-like domain of Cbl-b [9] . To assess whether this is also true for the Zap-70-Cbl-b interaction, Jurkat-TAg cells were cotransfected with a plasmid encoding Zap-70 together with a plasmid encoding the amino-terminal 349 amino acids of Cbl-b, Cbl-b(N), or a mutant form of this fragment containing the G298E mutation. Cell lysates were immunoprecipitated with antiCbl-b antibody and then immunoblotted with anti-phosphotyrosine antibody. As demonstrated for full-length Cbl-b and the G298E Cbl-b mutant (Figure 2b ), the form of Cbl-b(N) containing the G298E mutation did not interact with Zap-70 (Figure 2d ), indicating that the observed Zap-70-Cbl-b interaction is mediated via the aminoterminal portion of Cbl-b.
The similar interaction between full-length Cbl-b or Cbl-b(N) and Zap-70 prompted us to assess a functional role for Cbl-b(N) in NFAT activation. Unlike full-length Cbl-b, Cbl-b(N) did not induce NFAT activation under resting conditions (Figure 3a) , and in fact decreased NFAT activation under anti-CD3-stimulated conditions. This result implies that, by binding to may play a dominant-negative role in events downstream of Cbl-b. To test this hypothesis, we cotransfected a plasmid encoding Cbl-b with plasmids encoding Cbl-b(N) or the G298E Cbl-b(N) mutant and the NFAT-luc reporter plasmid, and assessed their respective effects on NFAT activation. As shown in Figure 3b (1:500), or with ionomycin (iono; 100 ng/ml) for 6-10 h. Cells were then lysed and the luciferase activity was determined as described previously and expressed in arbitrary units (AU) [17] . (b) Cells were transfected with empty vector (control), plasmids encoding Cbl-b or Cbl (5 µg each) plus 5 µg NFAT-luc reporter plasmid. At 24 h after transfection, cells were either left unstimulated or stimulated with different amounts of anti-CD3 antibody (OKT3; µl) at a dilution of 1:10 for 6-10 h. Lysates were then assayed for luciferase activity. In summary, we demonstrate that overexpression of Cblb induces the constitutive transactivation of NFAT, which is further enhanced by anti-CD3 stimulation. This effect is mediated by a direct interaction between the Cbl-b PTB domain and the Tyr292 residue of Zap-70, as a loss-of-function mutation (G298E) in Cbl-b disrupted its interaction with Zap-70 and abolished Cbl-b-induced NFAT activation.
Accumulating evidence suggests that Cbl is a negative regulator of intracellular signaling: Cbl-deficient mice display lymphoid hyperplasia, and thymocytes from these mice exhibit elevated levels of Zap-70 kinase activity [5] ;
Cbl directly inhibits the kinase activity of Syk [4] , and the TCR-induced activation of NFAT ( Figure 1 ) and AP-1 [14] ; and Cbl is involved in the hyporesponsiveness of anergic T cells [15] . Although the Cbl-Grb2 interaction [14] or the Cbl-Crk-L-Rap-1 signaling pathway [15] are thought to be responsible for the negative role of Cbl, a direct interaction between Cbl and Zap-70 [5] and/or Syk kinases in lymphocyte development and activation [16] , it can be envisioned that a delicate functional balance between Cbl and Cbl-b may have a significant impact on these kinase-mediated immune responses.
Supplementary material
Additional data on the specificity of Cbl-b in NFAT activation and additional methodological detail are published with this paper on the internet. 
Supplementary results
To ensure that the observed NFAT activation by Cbl-b was not a non-specific effect due to Cbl-b overexpression, we normalized the luciferase activity in relation to that induced by a combination of PMA and ionomycin stimulation. Under our experimental conditions, the maximal luciferase activity induced by PMA and ionomycin was normally about five times higher than that induced by anti-CD3 stimulation and no significant difference among different transfections was observed. As shown in Figure S1a , a similar pattern of the relative luciferase activity was observed, when normalized to the luciferase activity induced by PMA and ionomycin. As a further control, we cotransfected a plasmid containing β-galactosidase and the NFAT-luc reporter plasmid and empty vector or Cbl-b plasmid. When the luciferase activity was normalized to β-galactosidase activity, Cbl-b also induced a high level of NFAT activation under resting conditions that was enhanced by anti-CD3 stimulation ( Figure S1b ). It should be mentioned that coexpression with β-galactosidase caused a marked reduction in NFAT activity (~80%) (compare Figure S1b with Figure 1a) , probably due to the interference of the β-galactosidase enzyme. Due to the similarity of all three methods, in the following experiments we adopted a simple method as in Figure 1a to present our luciferase data.
The IL-2-gene-derived NFAT transcriptional unit used in this study contains a binding site for the NFAT transcription factor and a binding site for AP-1 [S1,S2]. The integration of a Ca 2+ -dependent and a Ras-dependent signal induces the transactivation of the promoter of the NFAT gene [S3-S5] . Next, we examined whether blockage of one of the two signals has any effect on Cbl-b-induced NFAT activation. As shown in Figure S2a , pretreatment of transfected cells with cyclosporin A (CsA), an inhibitor of calcineurin, reduced Cbl-b-induced NFAT activation under both basal and anti-CD3-stimulated conditions. Similarly, coexpression of a dominant-negative version of Ras, RasN17, almost completely abolished Cbl-b-induced NFAT activation under either resting or anti-CD3-stimulated conditions ( Figure S2b ). This effect of RasN17 did not reflect a non-specific inhibition of Cbl-b protein expression, as equivalent amounts of Cbl-b proteins were detected in the samples cotransfected with either the empty vector or plasmid encoding RasN17 ( Figure S2c ).
Supplementary discussion
In the present study, we have demonstrated that overexpression of Cbl-b induced constitutive transactivation of NFAT, which was enhanced by anti-CD3 stimulation. This Cbl-b-mediated effect requires a Ca 2+ signal and functional Ras, implying that the target of Cbl-b lies upstream of TCR-mediated signaling pathways. We
Supplementary material
Figure S1
Effects of Cbl-b on NFAT induction in Jurkat T cells. (a) Jurkat-TAg cells were transfected with empty vector (pEF) or plasmids encoding HA-tagged full-length Cbl-b (5 µg each) plus 5 µg NFAT-luc reporter plasmid. At 24 h after transfection, cells were left unstimulated (control), or stimulated with anti-CD3 (OKT3) ascites (1:500), ionomycin (iono; 100 ng/ml), or PMA (50 ng/ml) plus ionomycin (100 ng/ml) for 6-10 h. Cells were then lysed and the luciferase activity was determined. The relative luciferase activity was converted in relation to the maximal activity induced by PMA plus ionomycin. Two recent studies indicate that the Tyr292 residue of Zap-70 is a negative regulatory site: a Y292F Zap-70 mutant exhibits constitutive activation towards NFAT activation [S6,S7] . We recently observed the same result with a corresponding Syk Y316F mutant (our unpublished observations). Taken together, these results seem to agree with a hypothesis that these sites interact with a negative regulatory molecule(s). Thus, our data on Cbl-b as shown in the present study disagree with this model regarding the regulation of Syk/Zap-70. It is also shown, however, that Tyr292 is located in the linker region encompassing a negative regulatory domain, which contains binding sites for critically positive signaling molecules such as Vav [S8] . Removal of this linker region results in a Zap-70 mutant that is constitutively active [S7] . Thus, it is possible that the Y292F mutation of Zap-70 (or Y316F of Syk) may acquire a gain-of-function property via a structural change of this linker region, in addition to the disruption of its interaction with Cbl or Cbl-b. Clearly, future studies are needed to dissect the exact role of these binding sites for Cbl-family proteins in Zap-70 and Syk.
Our hypothesis that binding to Tyr292 of Zap-70 transduces either a positive and a negative signal is supported by the observation that Cbl-b(N), while still retaining the ability to bind Zap-70, does not induce constitutive activation of NFAT. Rather, it functions as a dominant-negative regulator of Cbl-b-induced NFAT activation. In addition, this inhibitory effect of Cbl-b(N) is markedly alleviated by the G298E mutation, suggesting that a direct interaction with Zap-70 accounts for the inhibitory function of Cbl-b(N). Consistent with this observation is our previous work on a Cbl-b fragment corresponding to Cbl-b(N), v-Cbl, which also interacts with Zap-70 [S9] , but is unable to induce NFAT activation under either resting or ionomycin-stimulated conditions [S10] .
The constitutive activation of NFAT by Cbl-b is reminiscent of an oncogenic Cbl mutant (70Z), which also causes constitutive NFAT activation [S10] . Both proteins require a Ca 2+ signal and functional Ras to exert their effects, implying that their targets of action are upstream of these two signals. Indeed, we recently demonstrated that a similar loss-of-function mutation in 70Z has the same effect as Cbl-b G298E on NFAT activation, suggesting these two molecules employ a common mechanism, that is, direct targeting of their upstream binding protein Zap-70. One obvious difference between these two molecules is that 70Z but not Cbl-b synergizes with ionomycin treatment [S10] (Figure 1) . Another difference is that while Cbl-b enhances anti-CD3-induced NFAT activation, 70Z inhibits this event [S11] . Although the exact Recently, a Cbl-Crk-L-Rap1 signal has been proposed to be responsible for T-cell anergy [S14] . It can be speculated that under anti-CD3-stimulated conditions, Cbl-b can also transduce a negative signal(s). A functional balance between positive and negative signals will determine the effect of Cbl-b on NFAT activation under anti-CD3-stimulated conditions. Other critical signaling molecules in T-cell activation such as Syk ( Figure S3 ) or LAT [S15] do not synergize with TCR ligation either.
The functional implication of Cbl family proteins in the regulation of receptor-mediated signaling is further complicated by several other studies showing that Cbl, a negative regulator, also functions as a positive regulator of intracellular signal transduction: Cbl was reported to positively regulate a Src-mediated signaling pathway leading to bone resorption [S16] , IL-4-induced cell proliferation [S17] or integrin-mediated cell spreading or cell adhesion [S18,S19] , in addition to its attributed role as a negative regulator. Similarly, it was reported that Cbl-b binds Vav and inhibits Vav-mediated activation of Jun N-terminal kinase [S20,S21] , although we do not observe a Cbl-b-Vav interaction in Jurkat T cells even when both Cbl-b and Vav are overexpressed [S12] . At present, the exact mechanism for the dual function of Cbl and/or Cbl-b remains unclear. These findings suggest, however, that both Cbl and/or Cbl-b can function as positive or negative regulators, depending on the specific signaling pathway and/or the particular cellular context. Clearly, additional studies are needed to elucidate the role(s) of Cbl-b and/or Cbl in intracellular signaling pathways. The current findings provide a framework for future studies on the function of Cbl-family proteins in TCR-mediated signal transduction, which may be crucial for the understanding of these molecules in the regulation of both normal and aberrant T cell responses.
Supplementary materials and methods

Antibodies
Polyclonal rabbit anti-Cbl-b (N-19 and H-121) antibodies were from Santa Cruz Biotechnology. A polyclonal rabbit anti-Cbl-b antibody suitable for immunoblotting was from O. Rosnet. Anti-phosphotyrosine monoclonal antibody 4G10 was from Upstate Biotechnology. Antihemagglutinin (HA) monoclonal antibody (12CA5) was from Boehringer Mannheim. Anti-Zap-70 monoclonal antibody was from Transduction Lab. Anti-CD3ε monoclonal antibody, OKT3, was purified from ascities using a protein-G-Sepharose affinity column. Horseradish peroxidase-conjugated F(ab′) 2 fragments of donkey anti-rabbit IgG or sheep anti-mouse IgG were from Amersham.
Plasmids
The Cbl-b cDNAs encoding full-length protein (Cbl-b; amino acids 1-982), its amino-terminal region (Cbl-b(N); amino acids 1-349), a lossof-function mutation (G298E) of Cbl-b(N), with an HA epitope at the carboxy-terminal end in an elongation factor promoter-driven mammalian vector were described previously [S12,S22] . A G298E mutation in fulllength Cbl-b was made by site-directed mutagenesis (QuickChange, Stratagene). The NFAT-luc reporter plasmid was kindly provided by G. Crabtree. Plasmids encoding wild-type human Zap-70 or β-galactosidase in pEFneo were constructed in this lab. A plasmid encoding human Zap-70 with a Y272F mutation was from A. Chan. A dominant-negative Ras construct (RasN17) was described previously [S10] .
Cell culture, transfection, and stimulation
Simian virus 40 T antigen (TAg)-transfected human leukemic Jurkat T cells (Jurkat-TAg) were grown in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum and antibiotics. For protein expression in Jurkat-TAg cells, cells were transfected with appropriate amounts of plasmids (usually 3-10 µg total) by electroporation as previously described [S22] . For phosphotyrosine studies, cells were resuspended (2 × 10 7 /ml) in 0.5 ml medium, equilibrated at 37°C for 5 min, and activated with OKT3 (4 µg/ml) for 5 min. Stimulation was terminated by adding 0.5 ml 2× Nonidet P-40 (NP-40) lysis buffer (2%
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Figure S3
Comparison of Cbl proteins with Syk in the induction of NFAT transactivation. The experiment was performed as in Figure 1b . Cells were also transfected with a plasmid containing Syk cDNA (5 µg) for comparison. As shown here, Syk did not synergize with the TCRinduced signal to induce NFAT transactivation. NP-40, 40 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10 mM EDTA, 10 mM NaPiP, 10 mM NaF, 4 mM Na 3 VO 4 , 20 µg/ml each aprotinin and leupeptin). Cells were lysed for 10 min at 4°C and insoluble materials were removed by centrifugation at 15,000 × g (4°C for 10 min). For luciferase assays, cells were washed, resuspended in RPMI 1640 medium containing 0.2% FCS and incubated for 4-6 h in 24-well plates. The cells were then left unstimulated or stimulated with either purified OKT3 (4 µg/ml) or OKT3 ascites (1:500), ionomycin (100 ng/ml), or PMA (50 ng/ml) for another 8-10 h.
Immunoprecipitation and immunoblotting
Lysates (~1 × 10 7 cells) were mixed with antibodies for 2 h, followed by addition of 40 µl protein A/G Plus-Sepharose beads (Santa Cruz Biotechnology) for an additional hour at 4°C. Immunoprecipitates were washed four times with 1× NP-40 lysis buffer, and boiled in 20 µl 2× Laemmli buffer. Samples were subjected to SDS/10% polyacrylamide gel electrophoresis (PAGE) analysis and electrotransferred onto polyvinylidene difluoride (PVDF) membranes (Millipore). Membranes were immunoblotted with the indicated primary antibodies (1 µg/ml), followed by horseradish-peroxidase-conjugated secondary antibodies. Membranes were then washed and visualized with enhanced chemiluminescence (ECL) detection system (Amersham). When necessary, membranes were stripped by incubation in 62.5 mM Tris-HCl, pH 6.7/100 mM 2-mercaptoethanol/2% SDS for 1 h at 70°C with constant agitation, washed, and then reprobed with other antibodies as indicated.
Luciferase assay
The luciferase assay to determine the activation of reporter genes was described previously [S10] . Luciferase activity was determined in triplicate and expressed as arbitrary units (AU). The standard deviation among triplicates was ≤10%, and each experiment was repeated at least three times. As a proper control for transfection, cells were also cotransfected with a pEF plasmid encoding β-galactosidase (3 µg per sample).
A portion of the cell lysates were analyzed for the enzyme activity using o-nitrophenyl-β-D-galatopyranoside as a substrate. The relative luciferase activity was normalized to the galactosidase enzymatic activity.
